Ocuphire Pharma Incentivizes Director Pepose with Stocks and Options

Ocuphire Pharma (OCUP) has issued an announcement.

Ocuphire Pharma, Inc. has engaged board director Dr. Jay Pepose as a consultant, compensating him with a monthly fee of $39,583, 32,000 restricted stock units, and options for 48,000 shares at $1.79 each. These incentives will vest over a year, incentivizing Dr. Pepose’s continued involvement with the company until the Consulting Agreement’s end date of April 11, 2025, signaling strategic moves that may interest stock market enthusiasts.

For an in-depth examination of OCUP stock, go to TipRanks’ Stock Analysis page.